Recent Advances in Mainstream Hemostasis Diagnostics and Coagulation Testing

Emmanuel J. Favaloro; Giuseppe Lippi

doi:10.1055/s-0038-1676579

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2019; 45(03): 228-246
DOI: 10.1055/s-0038-1676579

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Recent Advances in Mainstream Hemostasis Diagnostics and Coagulation Testing

Emmanuel J. Favaloro

¹Department of Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital, Westmead, NSW, Australia

,

Giuseppe Lippi

²Section of Clinical Biochemistry, University of Verona, Verona, Italy

› Author Affiliations

Abstract

The authors provide a narrative review of mainstream hemostasis analyzers. The review is presented in two parts. In the first part, the authors give voice to several internationally representative manufacturers of mainstream hemostasis analyzers. They ask these manufacturers to (1) answer a series of survey questions that may otherwise reflect common questions asked by users or potential users of their equipment, (2) provide a bullet list of their main focus areas, and (3) provide other information in regard to their instrumentation. The authors then offer their own personal perspective of the benefits of various aspects of such equipment, as well as a sampling of some hemostasis tests as currently available, or potentially in progress. It is hoped that this snapshot of mainstream hemostasis diagnostics and coagulation testing drives positive future changes that will ultimately provide the best outcomes for laboratories performing hemostasis assays and the patients they help diagnose and manage.

Keywords

hemostasis - analyzer - instrumentation - equipment - coagulation - testing

Full Text

References

References
1 Van Cott EM, Smock KJ, Lippi G. Innovations in thrombosis and hemostasis: a glimpse towards the future of diagnostic analyzers. Semin Thromb Hemost 2019; 45 (03) 225-227
2 Lippi G, Pasalic L, Favaloro EJ. Detection of mild inherited disorders of blood coagulation: current options and personal recommendations. Expert Rev Hematol 2015; 8 (04) 527-542
3 Lippi G, Favaloro EJ. Reflections on the next generation of hemostasis instrumentation. A glimpse into the future?. J Lab Med 2016; 40 (01) 1-7
4 Bonar RA, Lippi G, Favaloro EJ. Overview of hemostasis and thrombosis and contribution of laboratory testing to diagnosis and management of hemostasis and thrombosis disorders. Methods Mol Biol 2017; 1646: 3-27
5 Lippi G, Plebani M, Favaloro EJ. The changing face of hemostasis testing in modern laboratories: consolidation, automation, and beyond. Semin Thromb Hemost 2015; 41 (03) 294-299
6 Lippi G, Plebani M, Favaloro EJ. Technological advances in the hemostasis laboratory. Semin Thromb Hemost 2014; 40 (02) 178-185
7 Lippi G, Ippolito L, Favaloro EJ. Technical evaluation of the novel preanalytical module on instrumentation laboratory ACL TOP: advancing automation in hemostasis testing. J Lab Autom 2013; 18 (05) 382-390
8 Lippi G, Salvagno GL, Poli G, Gelati M, Favaloro EJ. Assessment of plasma sample quality on Siemens Atellica COAG 360 System. Semin Thromb Hemost 2019; 45 (03) 315-318
9 Favaloro EJ, Mohammed S. Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease. Thromb Res 2016; 141: 202-211
10 Lippi G, Favaloro EJ. Preanalytical issues in hemostasis and thrombosis testing. Methods Mol Biol 2017; 1646: 29-42
11 Favaloro EJ, Lippi G. Preanalytical issues that may cause misdiagnosis in haemophilia and von Willebrand disease. Haemophilia 2018; 24 (02) 198-210
12 Favaloro EJ, , Funk (Adcock) DM, Lippi G. Preanalytical variables in coagulation testing associated to diagnostic errors in hemostasis. Lab Med 2012; 43 (02) 1-10
13 Lippi G, Salvagno GL, Montagnana M, Lima-Oliveira G, Guidi GC, Favaloro EJ. Quality standards for sample collection in coagulation testing. Semin Thromb Hemost 2012; 38 (06) 565-575
14 Favaloro EJ, Oliver S, Mohammed S. , et al. Potential misdiagnosis of von Willebrand disease and haemophilia caused by ineffective mixing of thawed plasma. Haemophilia 2017; 23 (05) e436-e443
15 Lima-Oliveira G, Adcock DM, Salvagno GL, Favaloro EJ, Lippi G. Mixing of thawed coagulation samples prior to testing: is any technique better than another?. Clin Biochem 2016; 49 (18) 1399-1401
16 Adcock Funk DM, Lippi G, Favaloro EJ. Quality standards for sample processing, transportation, and storage in hemostasis testing. Semin Thromb Hemost 2012; 38 (06) 576-585
17 Lippi G, Plebani M, Favaloro EJ. Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. Semin Thromb Hemost 2013; 39 (03) 258-266
18 Lippi G, von Meyer A, Cadamuro J, Simundic AM. Blood sample quality. Diagnosis (Berl) 2018 . Doi: 10.1515/dx-2018-0018. [Epub ahead of print]
19 Da Rin G, Lippi G. Sample rerun after short-term refrigerated storage: impact on routine coagulation testing. Int J Lab Hematol 2014; 36 (05) e71-e73
20 Favaloro EJ, McVicker W, Lay M. , et al. Harmonizing the International Normalized Ratio (INR): standardization of methodologies and use of novel strategies to reduce inter-laboratory variation and bias. Am J Clin Pathol 2016; 145 (02) 191-202
21 Bonar R, Favaloro EJ. Explaining and reducing the variation in inter-laboratory reported values for International Normalised Ratio. Thromb Res 2017; 150: 22-29
22 Bonar R, Mohammed S, Favaloro EJ. International normalized ratio monitoring of vitamin K antagonist therapy: comparative performance of point-of-care and laboratory-derived testing. Semin Thromb Hemost 2015; 41 (03) 279-286
23 Lippi G, Favaloro EJ. Hemostasis practice: state-of-the-art. J Lab Precis Med 2018; 3: 67
24 Frère C, Kobayashi K, Dunois C, Amiral J, Morange PE, Alessi MC. Assessment of platelet function on the routine coagulation analyzer Sysmex CS-2000i. Platelets 2018; 29 (01) 95-97
25 Ling LQ, Liao J, Niu Q. , et al. Evaluation of an automated light transmission aggregometry. Platelets 2017; 28 (07) 712-719
26 Rodgers S, Duncan E. Chromogenic factor VIII assays for improved diagnosis of hemophilia A. Methods Mol Biol 2017; 1646: 265-276
27 Ullman EF, Kirakossian H, Switchenko AC. , et al. Luminescent oxygen channeling assay (LOCI): sensitive, broadly applicable homogeneous immunoassay method. Clin Chem 1996; 42 (09) 1518-1526
28 Kappel A, Ehm M. Immunoassays for diagnosis of coagulation disorders. Hamostaseologie 2010; 30 (04) 194-201
29 Kappel A, Stephan S, Christ G. , et al. Coagulation assays based on the Luminescent Oxygen Channeling Immunoassay technology 1). Clin Chem Lab Med 2011; 49 (05) 855-860
30 Shima M, Thachil J, Nair SC, Srivastava A. ; Scientific and Standardization Committee. Towards standardization of clot waveform analysis and recommendations for its clinical applications. J Thromb Haemost 2013; 11 (07) 1417-1420
31 Laffan MA, Lester W, O'Donnell JS. , et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 2014; 167 (04) 453-465
32 Nichols WL, Hultin MB, James AH. , et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14 (02) 171-232
33 Favaloro EJ. Diagnosis or exclusion of von Willebrand disease using laboratory testing. Methods Mol Biol 2017; 1646: 391-402
34 Favaloro EJ, Pasalic L, Curnow J. Laboratory tests used to help diagnose von Willebrand disease: an update. Pathology 2016; 48 (04) 303-318
35 Favaloro EJ, Bonar RA, Meiring M. , et al. Evaluating errors in the laboratory identification of von Willebrand disease in the real world. Thromb Res 2014; 134 (02) 393-403
36 Dorgalaleh A, Tabibian S, Shiravand Y, Favaloro EJ. von Willebrand disease. In: Dorgalaleh A. , ed. Congenital Bleeding Disorders. Cham, Switzerland: Springer; 2018
37 Favaloro EJ, Mohammed S, Patzke J. Laboratory testing for von Willebrand factor antigen (VWF:Ag). Methods Mol Biol 2017; 1646: 403-416
38 Favaloro EJ, Mohammed S. Laboratory testing for von Willebrand factor collagen binding (VWF:CB). Methods Mol Biol 2017; 1646: 417-433
39 Favaloro EJ. Utility of the von Willebrand factor collagen binding assay in the diagnosis of von Willebrand disease. Am J Hematol 2017; 92 (01) 114-118
40 Mohammed S, Favaloro EJ. Laboratory testing for von Willebrand factor ristocetin cofactor (VWF:RCo). Methods Mol Biol 2017; 1646: 435-451
41 Patzke J, Favaloro EJ. Laboratory testing for von Willebrand factor activity by glycoprotein Ib binding assays (VWF:GPIb). Methods Mol Biol 2017; 1646: 453-460
42 Mohammed S, Favaloro EJ. Laboratory testing for von Willebrand factor: factor VIII binding (for 2N VWD). Methods Mol Biol 2017; 1646: 461-472
43 Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J. ; von Willebrand factor Subcommittee of the Standardization and Scientific Committee of the International Society for Thrombosis and Haemostasis. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (07) 1345-1350
44 Favaloro EJ, Mohammed S. Towards improved diagnosis of von Willebrand disease: comparative evaluations of several automated von Willebrand factor antigen and activity assays. Thromb Res 2014; 134 (06) 1292-1300
45 Duncan E, Rodgers S. One-stage factor VIII assays. Methods Mol Biol 2017; 1646: 247-263
46 Oliver S, Lau KKE, Chapman K, Favaloro EJ. Laboratory testing for Von Willebrand factor multimers. Methods Mol Biol 2017; 1646: 495-511
47 Favaloro EJ, Oliver S. Evaluation of a new commercial von Willebrand factor multimer assay. Haemophilia 2017; 23 (04) e373-e377
48 Favaloro EJ, Bonar R, Hollestelle MJ. , et al. Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: a large international cross-laboratory study. Thromb Res 2018; 166: 96-105
49 Favaloro EJ, Bonar R, Chapman K, Meiring M, Funk Adcock D. Differential sensitivity of von Willebrand factor ‘activity’ assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen binding and mAb-based assays. J Thromb Haemost 2012; 10 (06) 1043-1054
50 Favaloro EJ, Pasalic L, Curnow J. Monitoring therapy during treatment of von Willebrand disease. Semin Thromb Hemost 2017; 43 (03) 338-354
51 Gremmel T, Frelinger III AL, Michelson AD. Platelet physiology. Semin Thromb Hemost 2016; 42 (03) 191-204
52 Bouchard BA, Chapin J, Brummel-Ziedins KE, Durda P, Key NS, Tracy PB. Platelets and platelet-derived factor Va confer hemostatic competence in complete factor V deficiency. Blood 2015; 125 (23) 3647-3650
53 Favaloro EJ. Clinical utility of closure times using the platelet function analyzer-100/200. Am J Hematol 2017; 92 (04) 398-404
54 Hvas AM, Favaloro EJ. Platelet function analyzed by light transmission aggregometry. Methods Mol Biol 2017; 1646: 321-331
55 Fritsma GA, McGlasson DL. Whole blood platelet aggregometry. Methods Mol Biol 2017; 1646: 333-347
56 Hvas AM, Favaloro EJ. Platelet function testing in pediatric patients. Expert Rev Hematol 2017; 10 (04) 281-288
57 Frontroth JP, Favaloro EJ. Ristocetin-induced platelet aggregation (RIPA) and RIPA mixing studies. Methods Mol Biol 2017; 1646: 473-494
58 Rudzki Z, Duncan EM, Casey GJ, Neumann M, Favaloro EJ, Lloyd JV. Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Br J Haematol 1996; 94 (02) 400-406
59 Moser KA, Adcock Funk DM. Chromogenic factor VIII activity assay. Am J Hematol 2014; 89 (07) 781-784
60 Al-Samkari H, Croteau SE. Shifting landscape of hemophilia therapy: implications for current clinical laboratory coagulation assays. Am J Hematol 2018;
61 Kitchen S, Tiefenbacher S, Gosselin R. Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies. Semin Thromb Hemost 2017; 43 (03) 331-337
62 Kershaw GW, Dissanayake K, Chen VM, Khoo TL. Evaluation of chromogenic factor IX assays by automated protocols. Haemophilia 2018; 24 (03) 492-501
63 Favaloro EJ, Lippi G. Emerging treatments for hemophilia: patients and their treaters spoilt for choice, but laboratories face a difficult path?. Ann Transl Med 2017; 5 (05) 101
64 Favaloro EJ, McCaughan G, Pasalic L. Clinical and laboratory diagnosis of heparin induced thrombocytopenia: an update. Pathology 2017; 49 (04) 346-355
65 Favaloro EJ. Laboratory tests for identification or exclusion of heparin induced thrombocytopenia: HIT or miss?. Am J Hematol 2018; 93 (02) 308-314
66 Lau KKE, Mohammed S, Pasalic L, Favaloro EJ. Laboratory testing protocols for heparin-induced thrombocytopenia (HIT) testing. Methods Mol Biol 2017; 1646: 227-243
67 Favaloro EJ, McCaughan G, Mohammed S. , et al. HIT or miss? A comprehensive contemporary investigation of laboratory tests for heparin induced thrombocytopenia. Pathology 2018; 50 (04) 426-436
68 Berroëta C, Crespin M, Bouabdallah K. , et al. Diagnostic performance of a new rapid lateral flow immunoassay in patients suspected of heparin-induced thrombocytopenia and its clinical consequences. Semin Thromb Hemost 2016; 42 (01) 69-74
69 Thachil J, Lippi G, Favaloro EJ. D-dimer testing: laboratory aspects and current issues. Methods Mol Biol 2017; 1646: 91-104
70 Longstaff C, Adcock D, Olson JD. , et al. Harmonisation of D-dimer—a call for action. Thromb Res 2016; 137: 219-220
71 Lippi G, Tripodi A, Simundic AM, Favaloro EJ. International survey on D-dimer test reporting: a call for standardization. Semin Thromb Hemost 2015; 41 (03) 287-293
72 Lippi G, Mattiuzzi C, Cervellin G, Favaloro EJ. Direct oral anticoagulants: analysis of worldwide use and popularity using Google Trends. Ann Transl Med 2017; 5 (16) 322
73 Favaloro EJ, Pasalic L, Lippi G. Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for pathology testing. Pathology 2017; 49 (06) 639-643
74 Douxfils J, Gosselin RC. Laboratory assessment of direct oral anticoagulants. Semin Thromb Hemost 2017; 43 (03) 277-290
75 Lim HY, Nandurkar H, Ho P. direct oral anticoagulants and the paradigm shift in the management of venous thromboembolism. Semin Thromb Hemost 2018; 44 (03) 261-266
76 Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Calvo-Rojas G, Vargas-Castrillón E. Causes of death in patients with venous thromboembolism anticoagulated with direct oral anticoagulants: a systematic review and meta-analysis. Semin Thromb Hemost 2018; 44 (04) 377-387
77 Favaloro EJ, Pasalic L, Curnow J, Lippi G. Laboratory monitoring or measurement of direct oral anticoagulants (DOACs): advantages, limitations and future challenges. Curr Drug Metab 2017; 18 (07) 598-608
78 Gosselin RC, Adcock DM, Bates SM. , et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 2018; 118 (03) 437-450
79 Favaloro EJ, Lippi G. Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors. Semin Thromb Hemost 2015; 41 (02) 208-227
80 Bonar R, Favaloro EJ, Mohammed S, Pasalic L, Sioufi J, Marsden K. The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 2015; 47 (04) 355-364
81 Bonar R, Favaloro EJ, Mohammed S. , et al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 2016; 48 (01) 60-71
82 Favaloro EJ, Wong RC. Antiphospholipid antibody testing for the antiphospholipid syndrome: a comprehensive practical review including a synopsis of challenges and recent guidelines. Pathology 2014; 46 (06) 481-495
83 Urbanus RT. Recent developments in antiphospholipid antibodies and the antiphospholipid syndrome. Semin Thromb Hemost 2018; 44 (05) 417-418
84 Favaloro EJ, Wong RCW. Current clinical and laboratory practice for the investigation of the antiphospholipid syndrome: findings from the 2008 Australasian antiphospholipid antibody survey. Pathology 2009; 41 (07) 666-675
85 Montalvão S, Elídio PS, da Silva Saraiva S. , et al. Clinical implications of the detection of antibodies directed against domain 1 of β2-glycoprotein 1 in thrombotic antiphospholipid syndrome. Thromb Res 2016; 148: 32-37
86 Nojima J, Motoki Y, Hara K, Sakata T, Ichihara K. Novel enzyme immunoassay system for simultaneous detection of six subclasses of antiphospholipid antibodies for differential diagnosis of antiphospholipid syndrome. Blood Coagul Fibrinolysis 2017; 28 (04) 316-322
87 Favaloro EJ, Wheatland L, Jovanovich S, Roberts-Thomson P, Wong RCW. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I--Anticardiolipin and anti-β2-glycoprotein I antibodies. Semin Thromb Hemost 2012; 38 (04) 390-403
88 Favaloro EJ, Bonar R, Marsden K. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part II--Lupus anticoagulant. Semin Thromb Hemost 2012; 38 (04) 404-411
89 Favaloro EJ. Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants. Int J Lab Hematol 2013; 35 (03) 269-274
90 Favaloro EJ, Lippi G. Post-analytical issues in hemostasis and thrombosis testing. Methods Mol Biol 2017; 1646: 545-559
91 Favaloro EJ, Mohammed S, Lippi G. Postanalytical considerations that may improve the diagnosis or exclusion of haemophilia and von Willebrand disease. Haemophilia 2018; 24 (06) 849-861
92 Poli G, Castiglioni P, Montagnana M, Favaloro EJ, Lippi G. Troubleshooting an isolate prolongation of activated partial thromboplastin time in a patient with acute myocardial infarction-a paradigmatic case report. Ann Transl Med 2016; 4 (21) 426
93 Baluwala I, Favaloro EJ, Pasalic L. Therapeutic monitoring of unfractionated heparin - trials and tribulations. Expert Rev Hematol 2017; 10 (07) 595-605
94 Laposata ME, Laposata M, Van Cott EM, Buchner DS, Kashalo MS, Dighe AS. Physician survey of a laboratory medicine interpretive service and evaluation of the influence of interpretations on laboratory test ordering. Arch Pathol Lab Med 2004; 128 (12) 1424-1427
95 Favaloro EJ, Lippi G. On the complexity of hemostasis and the need for harmonization of test practice. Clin Chem Lab Med 2018; 56 (10) 1568-1574
96 Favaloro EJ, Gosselin R, Olson J, Jennings I, Lippi G. Recent initiatives in harmonization of hemostasis practice. Clin Chem Lab Med 2018; 56 (10) 1608-1619
97 Favaloro EJ, Jennings I, Olson J. , et al. Towards harmonization of external quality assessment/proficiency testing in hemostasis. Clin Chem Lab Med 2018; 57 (01) 115-126